vs
Side-by-side financial comparison of AMC Networks Inc. (AMCX) and Hologic (HOLX). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $594.8M, roughly 1.8× AMC Networks Inc.). Hologic runs the higher net margin — 17.1% vs -9.3%, a 26.4% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs -0.8%). Hologic produced more free cash flow last quarter ($215.2M vs $40.4M). Over the past eight quarters, Hologic's revenue compounded faster (1.5% CAGR vs -0.1%).
AMC Networks Inc. is an American independent mass media and entertainment corporation headquartered in 11 Penn Plaza, New York City. The company owns and operates the eponymous cable channel, BBC America, IFC, Sundance TV, and We TV. It also owns the art house movie theater IFC Center in New York City; the independent film companies Independent Film Company and RLJE Films, the anime licensor Sentai Filmworks, the premium subscription streaming services AMC+, IFC Films Unlimited, Acorn TV, All...
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
AMCX vs HOLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $594.8M | $1.0B |
| Net Profit | $-55.5M | $179.1M |
| Gross Margin | 49.7% | 56.0% |
| Operating Margin | -8.6% | 22.6% |
| Net Margin | -9.3% | 17.1% |
| Revenue YoY | -0.8% | 2.5% |
| Net Profit YoY | 80.5% | -10.9% |
| EPS (diluted) | $-0.97 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $594.8M | $1.0B | ||
| Q3 25 | $561.7M | $1.0B | ||
| Q2 25 | $600.0M | $1.0B | ||
| Q1 25 | $555.2M | $1.0B | ||
| Q4 24 | $599.3M | $1.0B | ||
| Q3 24 | $599.6M | $988.0M | ||
| Q2 24 | $625.9M | $1.0B | ||
| Q1 24 | $596.5M | $1.0B |
| Q4 25 | $-55.5M | $179.1M | ||
| Q3 25 | $76.5M | $187.2M | ||
| Q2 25 | $50.3M | $194.9M | ||
| Q1 25 | $18.0M | $-17.4M | ||
| Q4 24 | $-284.5M | $201.0M | ||
| Q3 24 | $41.4M | $178.6M | ||
| Q2 24 | $-29.2M | $194.5M | ||
| Q1 24 | $45.8M | $169.9M |
| Q4 25 | 49.7% | 56.0% | ||
| Q3 25 | 48.2% | 55.6% | ||
| Q2 25 | 52.7% | 56.3% | ||
| Q1 25 | 51.8% | 37.5% | ||
| Q4 24 | 51.2% | 56.8% | ||
| Q3 24 | 52.0% | 56.4% | ||
| Q2 24 | 55.2% | 55.4% | ||
| Q1 24 | 54.5% | 53.3% |
| Q4 25 | -8.6% | 22.6% | ||
| Q3 25 | 9.9% | 22.6% | ||
| Q2 25 | 10.7% | 24.9% | ||
| Q1 25 | 11.6% | -0.7% | ||
| Q4 24 | -42.4% | 22.5% | ||
| Q3 24 | 15.6% | 23.3% | ||
| Q2 24 | 1.7% | 24.1% | ||
| Q1 24 | 18.5% | 20.7% |
| Q4 25 | -9.3% | 17.1% | ||
| Q3 25 | 13.6% | 17.8% | ||
| Q2 25 | 8.4% | 19.0% | ||
| Q1 25 | 3.3% | -1.7% | ||
| Q4 24 | -47.5% | 19.7% | ||
| Q3 24 | 6.9% | 18.1% | ||
| Q2 24 | -4.7% | 19.2% | ||
| Q1 24 | 7.7% | 16.7% |
| Q4 25 | $-0.97 | $0.79 | ||
| Q3 25 | $1.38 | $0.84 | ||
| Q2 25 | $0.91 | $0.86 | ||
| Q1 25 | $0.34 | $-0.08 | ||
| Q4 24 | $-6.23 | $0.87 | ||
| Q3 24 | $0.76 | $0.75 | ||
| Q2 24 | $-0.66 | $0.82 | ||
| Q1 24 | $1.03 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $502.4M | $2.4B |
| Total DebtLower is stronger | $1.8B | $2.5B |
| Stockholders' EquityBook value | $981.9M | $5.2B |
| Total Assets | $3.9B | $9.2B |
| Debt / EquityLower = less leverage | 1.78× | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $502.4M | $2.4B | ||
| Q3 25 | $716.8M | $2.2B | ||
| Q2 25 | $866.4M | $1.9B | ||
| Q1 25 | $870.2M | $1.6B | ||
| Q4 24 | $784.6M | $2.0B | ||
| Q3 24 | $816.4M | $2.3B | ||
| Q2 24 | $802.6M | $2.4B | ||
| Q1 24 | $690.5M | $2.2B |
| Q4 25 | $1.8B | $2.5B | ||
| Q3 25 | $1.9B | $2.5B | ||
| Q2 25 | $2.2B | $2.5B | ||
| Q1 25 | $2.3B | $2.5B | ||
| Q4 24 | $2.3B | $2.5B | ||
| Q3 24 | $2.3B | $2.5B | ||
| Q2 24 | $2.4B | $2.5B | ||
| Q1 24 | $2.3B | $2.6B |
| Q4 25 | $981.9M | $5.2B | ||
| Q3 25 | $1.1B | $5.0B | ||
| Q2 25 | $971.7M | $4.8B | ||
| Q1 25 | $888.8M | $4.6B | ||
| Q4 24 | $855.6M | $4.8B | ||
| Q3 24 | $1.1B | $5.1B | ||
| Q2 24 | $1.1B | $5.0B | ||
| Q1 24 | $1.1B | $4.8B |
| Q4 25 | $3.9B | $9.2B | ||
| Q3 25 | $4.2B | $9.0B | ||
| Q2 25 | $4.4B | $8.8B | ||
| Q1 25 | $4.3B | $8.5B | ||
| Q4 24 | $4.4B | $8.7B | ||
| Q3 24 | $4.8B | $9.2B | ||
| Q2 24 | $4.9B | $8.9B | ||
| Q1 24 | $4.9B | $8.7B |
| Q4 25 | 1.78× | 0.48× | ||
| Q3 25 | 1.82× | 0.50× | ||
| Q2 25 | 2.27× | 0.52× | ||
| Q1 25 | 2.62× | 0.55× | ||
| Q4 24 | 2.73× | 0.53× | ||
| Q3 24 | 2.10× | 0.49× | ||
| Q2 24 | 2.26× | 0.51× | ||
| Q1 24 | 2.17× | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $49.2M | $229.9M |
| Free Cash FlowOCF − Capex | $40.4M | $215.2M |
| FCF MarginFCF / Revenue | 6.8% | 20.5% |
| Capex IntensityCapex / Revenue | 1.5% | 1.4% |
| Cash ConversionOCF / Net Profit | — | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $272.4M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $49.2M | $229.9M | ||
| Q3 25 | $44.8M | $355.1M | ||
| Q2 25 | $102.8M | $343.3M | ||
| Q1 25 | $108.8M | $169.4M | ||
| Q4 24 | $58.1M | $189.3M | ||
| Q3 24 | $62.2M | $367.0M | ||
| Q2 24 | $104.4M | $405.8M | ||
| Q1 24 | $150.9M | $292.4M |
| Q4 25 | $40.4M | $215.2M | ||
| Q3 25 | $42.0M | $341.4M | ||
| Q2 25 | $95.7M | $330.5M | ||
| Q1 25 | $94.2M | $153.9M | ||
| Q4 24 | $37.6M | $172.5M | ||
| Q3 24 | $53.9M | $350.6M | ||
| Q2 24 | $95.2M | $385.3M | ||
| Q1 24 | $144.1M | $279.6M |
| Q4 25 | 6.8% | 20.5% | ||
| Q3 25 | 7.5% | 32.5% | ||
| Q2 25 | 16.0% | 32.3% | ||
| Q1 25 | 17.0% | 15.3% | ||
| Q4 24 | 6.3% | 16.9% | ||
| Q3 24 | 9.0% | 35.5% | ||
| Q2 24 | 15.2% | 38.1% | ||
| Q1 24 | 24.2% | 27.5% |
| Q4 25 | 1.5% | 1.4% | ||
| Q3 25 | 0.5% | 1.3% | ||
| Q2 25 | 1.2% | 1.3% | ||
| Q1 25 | 2.6% | 1.5% | ||
| Q4 24 | 3.4% | 1.6% | ||
| Q3 24 | 1.4% | 1.7% | ||
| Q2 24 | 1.5% | 2.0% | ||
| Q1 24 | 1.1% | 1.3% |
| Q4 25 | — | 1.28× | ||
| Q3 25 | 0.59× | 1.90× | ||
| Q2 25 | 2.04× | 1.76× | ||
| Q1 25 | 6.03× | — | ||
| Q4 24 | — | 0.94× | ||
| Q3 24 | 1.50× | 2.05× | ||
| Q2 24 | — | 2.09× | ||
| Q1 24 | 3.29× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMCX
| Subscription And Circulation | $314.8M | 53% |
| Advertising | $124.9M | 21% |
| Other | $79.1M | 13% |
| License | $74.8M | 13% |
| Related Party | $1.2M | 0% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
